Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers  by Gauthé, Mathieu et al.
RR
t
M
J
t
a
b
c
d
e
f
g
h
i
a
A
R
A
A
K
A
C
F
O
P
1
e
o
o
(
t
i
n
r
M
f
h
1Digestive and Liver Disease 47 (2015) 443–454
Contents lists available at ScienceDirect
Digestive  and  Liver  Disease
jou rna l h om epage: www.elsev ier .com/ locate /d ld
eview  Article
ole  of  ﬂuorine  18  ﬂuorodeoxyglucose  positron  emission
omography/computed  tomography  in  gastrointestinal  cancers
athieu  Gauthéa,b,∗,  Marion  Richard-Molardc,  Wulfran  Cacheuxd,  Pierre  Michele,f,
ean-Louis  Jouveg, Emmanuel  Mitryh,i, Jean-Louis  Alberinia,i, Astrid  Lièvreh,i, on  behalf  of
he  Fédération  Francophone  de  Cancérologie  Digestive  (FFCD)
Institut Curie, René Huguenin Hospital, Department of Nuclear Medicine, Saint-Cloud, France
Department of Nuclear Medicine, Centre Oscar Lambret, Lille, France
Institut Curie, René Huguenin Hospital, Department of Radiation Therapy, Saint-Cloud, France
Institut Curie, Department of Medical Oncology, Paris, France
Department of Gastroenterology, Rouen University Hospital, France
University of Rouen, Rouen, France
Department of Gastroenterology, Dijon University Hospital, University of Burgundy, INSERM U866, Dijon, France
Institut Curie, René Huguenin Hospital, Department of Medical Oncology, Saint-Cloud, France
University of Versailles Saint Quentin, Faculty of Health Sciences, Montigny-Le-Bretonneux, France
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 12 January 2015
ccepted 6 February 2015
vailable online 19 February 2015
eywords:
nal canal cancer
a  b  s  t  r  a  c  t
Fluorine-18  ﬂuorodeoxyglucose  positron  emission  tomography/computed  tomography  (FDG-PET/CT)
has  become  a  routine  imaging  modality  for many  malignancies  and  its  use  is  currently  increasing.  In
the present  review  article,  we  will  summarize  the  evidence  for  FDG-PET/CT  use  in digestive cancers
(excluding  neuroendocrine  tumours),  and  review  the  existing  recommendations.  While  PET/CT  is  nowa-
days  considered  to  be  an important  tool  in the  initial  workup  of  oesophageal  and  anal  cancers,  new  data
are emerging  regarding  its  use  in  assessing  therapeutic  efﬁcacy,  radiotherapy  treatment  planning,  andolorectal cancer
DG-PET/CT
esophageal cancer
ancreatic cancer
detection  of  recurrence  in case  of  isolated  tumour  marker  elevation.  Moreover,  PET/CT  may  help  decision
making  by detecting  distant  metastatic  sites  especially  in  potentially  resectable  metastatic  colorectal  can-
cer and,  to  a lesser  extent,  in  localized  gastric  and  pancreatic  cancers.  Finally,  incidental  focal  colonic  FDG
uptakes  require  exploration  by  colonoscopy,  as they  are  often  associated  with  premalignant  or  malignant
lesions.
© 2015  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.. Introduction
In oncology, morphological imaging is suitable for TN staging,
xcept for the detection of small metastatic lymph nodes, but is
f lesser value for the detection of distant metastases. The role
f ﬂuorine-18 ﬂuorodeoxyglucose positron emission tomography
FDG-PET) has evolved over the last two decades, particularly after
he diffusion of combined PET and computed tomography (CT)
maging in the early 2000s. FDG-PET/CT is used in gastrointesti-
al oncology for diagnosis, staging, follow-up for evaluation of
esponse to treatment, and detection of recurrence.
∗ Corresponding author at: Centre Oscar Lambret, Department of Nuclear
edicine, 3 Rue Frédéric Combemale, 59000 Lille, France. Tel.: +33 320295959;
ax: +33 320295962.
E-mail address: m-gauthe@o-lambret.fr (M.  Gauthé).
ttp://dx.doi.org/10.1016/j.dld.2015.02.005
590-8658/© 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. AllThe purpose of this article is to review the role of FDG-PET/CT
in the management of gastrointestinal cancers, excluding neuroen-
docrine tumours that would require a separate dissertation.
2. Esophageal cancer
2.1. Initial staging
FDG-PET is not sufﬁciently accurate for T staging [1] as compared
to the combination of endoscopic ultrasound (EUS) and thoracic,
abdominal, and pelvic CT scan, which have been shown to be the
most efﬁcient combined imaging techniques to evaluate the depth
of the primary tumour in the wall [2,3]. For loco-regional N staging,
false-positive results of FDG-PET have been shown to be related
to an inﬂammatory process [4]. However, FDG-PET/CT has a bet-
ter diagnostic performance than the combination of EUS and CT to
detect distant metastases, especially for extra-mediastinal lymph
 rights reserved.
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Fig. 1. Initial staging of a woman with oesophageal squamous cell carcinoma of the middle third of the oesophagus. Positron emission tomography maximum intensity
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projection image (A) and sagittal fused positron emission tomography/computed 
umour (a) (standardized uptake value max  14.8) and in a celiac lymph node (b) (st
odes (Fig. 1). In 2 meta-analyses published in 2004 and 2008, the
ooled sensitivity and speciﬁcity of FDG-PET for the detection of
istant metastases were 67% and 97% [5], and 71% and 93% [2],
espectively. FDG-PET ﬁndings led to a signiﬁcant change in patient
anagement in about one third of the patients in this indication
6,7].
Therefore, a diagnostic strategy including EUS, CT, and FDG-
ET/CT allows a more accurate initial staging of oesophageal
ancer. The impact on decision-making is crucial in order to dis-
riminate patients who are candidates for surgery, or exclusive
hemo-radiotherapy (CRT) with curative intent, from patients with
etastatic disease, for whom a local treatment is not feasible. Thus,
DG-PET/CT is recommended in non-metastatic oesophageal can-
er, a condition for which its use is likely to change the therapeutic
trategy [2,5,8,9].
.2. Assessment of therapeutic efﬁcacy/prognosis
Trimodality therapy, including neoadjuvant CRT and surgery,
as been shown to be superior to surgery alone [10–12]. Two
andomized phase III trials demonstrated no signiﬁcant overall
urvival (OS) beneﬁt of oesophagectomy compared to CRT or
hemotherapy alone in patients with locally advanced oesophageal
ancer who exhibited a clinical response to neoadjuvant therapy
13,14]. Therefore, deﬁnitive CRT has become a ﬁrst-line treat-
ent option in this subset of patients, and it is now essential to
elect subjects not exhibiting an early response to CRT so that
esophagectomy can be proposed prior to the onset of CRT toxicity.
Several studies have suggested a predictive value of metabolic
hanges for assessing early response to CRT and prognosis of
atients with locally advanced oesophageal cancer, but their resultsraphy image (B) showing ﬂuorodeoxyglucose uptake in the primary oesophageal
dixed uptake value max 12.1).
vary according to the metabolic parameter considered (Table 1)
[15–26].
Although a high pre-treatment maximum standard uptake value
(SUVmax) or metabolic tumour volume (MTV) on the primary
tumour are prognostic factors for poor OS [27–30], many studies
assessing SUVmax changes in response to therapy (chemother-
apy or CRT) as a prognostic factor have reported conﬂicting results
[22,24–26,29–33]. In fact, various parameters, in addition to the
metabolic factor speciﬁcally studied, can interfere with response
to neoadjuvant therapy and can account for these heterogeneous
ﬁndings. For example, PET/CT appears to be more useful when
evaluating response to chemotherapy [15,20–22] than response
to CRT (presumably because of the inﬂammatory phenomena)
[16–19,23–26,29–31,34]. Moreover, the tumour histological type
seems to play an important role, with better PET/CT performances
in squamous cell carcinomas (SCC) [16,17,29–31] than in adeno-
carcinomas (ADK) [15,20–23].
Cuenca et al. recently analysed a mixed population of SCC and
ADK with a large majority of SCC (41 vs. 18), and reported that a
decrease greater than 50% in SUVmax 5 weeks after CRT induction
was correlated with survival [34]; however, Piessen et al. did not
demonstrate any correlation between SUV, histological response,
and long-term survival in a balanced population of SCC and ADK
(21 SCC vs 25 ADK) [26].
In conclusion, as oesophagectomy did not appear to signiﬁcantly
improve survival in locally advanced oesophageal cancer patients
with a good response to neoadjuvant therapy [35], it is crucial to
develop reliable tools in order to monitor tumour response. The
predictive value of FDG-PET/CT for tumour response is a subject
of debate and its value in this setting has not yet been validated.
Multicentre randomized trials are therefore required.
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Table  1
Major studies assessing ﬂuorodeoxyglucose positron emission tomography performances for predicting histological response and survival.
References n Histology Neoadjuvant
therapy
Operated
patients
Metabolic
parameter
Considered
cutoff
FDG PET predictive values Median OS MR
vs. nonMR
PPV PNV
Weber 2001 [15] 40 ADK Ch 35 intSUV 35% 53% 95% nr vs. 19
months
(p = 0.04)
Wieder 2004 [16] 38 SCC CRT 33 intSUV 30% 93% 88% 38 vs. 18
months
(p = 0.01)
Song  2005 [17] 32 SCC CRT 32 endSUV 52% 75% (T)
36% (N)
71% (T)
93% (N)
–
Levine 2006 [18] 49 ADK
and SCC
CRT 41 end SUV 4 82.6% (T)
82.4% (N)
55.6% (M)
33.3% (T)
92.3% (N)
96.7% (M)
36 vs. 24
months
(p = 0.4)
Ott  2006 [20] 65 ADK Ch 50 intSUV 35% 44% 95% nr vs. 18
months
(p = 0.01)
Wieder 2007 [21] 24 ADK Ch 24 intSUV 33% – – 83% vs. 33%
(p = 0.03)
Lordick  2007 [22] 119 ADK Ch 104 intSUV 35% 58% – nr vs.
25.8months
(p = 0.01)
van  Heijl 2011
[25]
154 ADK
and SCC
CRT 100 intSUV Any change 76% 75% –
10% 76% 63%
20% 78% 55%
30% 75% 45%
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NV,  predictive negative value; OS, overall survival; intSUV, differences between S
t  the end of neoadjuvant therapy; endSUV, SUV value at the end of neoadjuvant th
.3. Radiotherapy treatment planning
The use of FDG-PET data in radiotherapy CT simulation would
hange the extent of radiation ﬁelds by more or less 20% in about
alf of the patients [35–38]. Conversely these changes could affect
he extent of primary tumour and/or locoregional lymph nodes to
e included in the radiation ﬁelds [35–38]. However, only limited
iterature is available on this subject, and the value of FDG-PET/CT
n radiotherapy treatment planning remains to be validated.
.4. Detection of recurrence
Detection of recurrence by imaging techniques is challenging
ue to the tissue changes induced by surgery and/or radiother-
py. In this setting, FDG-PET/CT appears to have a high positive
redictive value (PPV) and a low negative predictive value (NPV)
39–41].
However, the available data are insufﬁcient to draw any con-
lusion and FDG-PET/CT cannot be widely recommended in this
etting.
.5. Current guidelines
The French Digestive Oncology Federation (FFCD), the National
omprehensive Cancer Network (NCCN), and the European Society
or Medical Oncology (ESMO) recommend performing PET/CT for
nitial staging when there is no evidence of M1  disease (candidates
or surgical resection) [9,42,43]. In addition, the NCCN recommends
ET/CT for radiotherapy treatment planning, and recommends con-
ideration of PET/CT for the assessment of response to preoperative
r deﬁnitive CRT before surgery or initiation of adjuvant therapy
42].
While the beneﬁt of PET/CT for oesophageal cancer staging
as now been clearly established, a positive or ambiguous distant
etastasis at PET should not lead to denial of those therapeu-
ic options, like radiotherapy, that may  be useful to achieve
umour local control, especially in symptomatic patients. Emergingmoradiotherapy; SUV, standardized uptake value; PPV, predictive positive value;
o  weeks after neoadjuvant therapy initiation; endSUV, differences between SUV
; MR,  metabolic responders; nonMR, non metabolic responders; nr, not reached.
evidence concerning its value for radiotherapy treatment planning
suggests that this imaging modality should be considered in this
indication. A standard metabolic parameter needs to be validated
before routine use of FDG-PET/CT for assessment of therapeutic
efﬁcacy.
3. Gastric cancer
3.1. Initial staging
FDG-PET/CT is associated with a low detection rate for the diag-
nosis of primary gastric cancer (about 55%), especially for early
gastric cancer, as well as signet-ring cell, mucinous, and poorly
differentiated adenocarcinomas, which are typically less metabol-
ically active [44–52]. Moreover, variable and occasionally intense
physiological uptake within the gastric wall is not uncommon and
may  mask FDG uptake by the primary tumour. Increased FDG
uptake may  also correspond to the presence of gastritis. Therefore,
FDG-PET/CT has no role in the diagnosis and T staging of gastric
cancer.
Although FDG-PET/CT appears to be more speciﬁc for the detec-
tion of local or loco-regional lymph nodes and peritoneal lesions
than CT scanning, it is less sensitive. These results can be explained
by the usually small size of these lesions [46,53–57]. However, the
addition of PET/CT to CT, EUS, and laparoscopy has been shown
to improve preoperative TNM staging and, therefore, inﬂuence
decision-making. After this complete workup, gastrectomy was
shown to be unnecessary in 6–10% of patients, leading to potential
savings of about $10,000 per patient [53,58].
3.2. Detection of recurrence
Disease recurrence frequently occurs locally and in areas dam-
aged by surgery that have lost their usual anatomic features.
Glucose metabolism is typically low in scar tissue and high in recur-
rent tumour. FDG-PET has demonstrated good performances for the
detection of gastric cancer recurrence, but not superior to those of
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T scan [59]. The use of FDG-PET does not appear to be relevant for
his purpose.
.3. Current guidelines
The NCCN recommends PET/CT for initial staging when there is
o evidence of metastatic disease [42]. However, the low impact
f this imaging technique on the therapeutic strategy reported in
he literature, together with its limited accessibility, discourages its
ystematic use in this setting. The FFCD and ESMO have not issued
ny clear recommendation concerning the use of PET/CT in gastric
ancer [9,60], and its role in the management of this type of cancer
eeds to be conﬁrmed.
. Pancreatic cancer
.1. Diagnosis of malignancy
Glucose intolerance is frequently encountered in patients with
ancreatic diseases. An elevated serum glucose level can induce a
ecreased FDG uptake in the pancreatic tumour and can even lead
o false-negative PET ﬁndings [61]. In subjects with normal blood
lucose levels (<7.2 mmol/L), PET/CT has shown high sensitivity
85–100%) and speciﬁcity (67–99%) for distinguishing between
enign and malignant pancreatic masses, and for differentiating
hronic pancreatitis and autoimmune pancreatitis from pancreatic
ancer [62–69].
The performances of PET/CT for establishing the diagnosis of
alignancy in pancreatic lesions have been shown to be equiva-
ent or superior to those of PET and CT alone [70–72] or magnetic
esonance imaging (MRI) [73], but comparable to those of EUS [64].
.2. Initial staging
PET/CT has been reported to have sensitivities ranging from 85%
o 89% and speciﬁcities from 55% to 94% for initial staging of pan-
reatic cancer, especially for the detection of distant metastases
64,73–78]. PET/CT has been reported to change the therapeutic
trategy in 16–41% of patients by providing more accurate staging
f pancreatic cancer, and this would be cost-effective by prevent-
ng unnecessary surgery or surgical intervention [62,74]. However,
ts added value compared to MRI  and EUS, which are essential in
oco-regional staging before surgery, has not been evaluated.
.3. Assessment of therapeutic efﬁcacy/prognosis
FDG-PET has been shown to be more accurate than CT scanning
n evaluating tumour response by providing information on tumour
ell viability. Conversely, measurement of tumour response by CT,
hich is the reference morphological imaging modality, is essen-
ially based on lesion dimensions [79,80]. CT appears to be unable to
istinguish the tumour from necrotic or ﬁbrotic processes induced
y chemotherapy or CRT [79,80]. It would be of interest to iden-
ify good responders to chemotherapy, with initially unresectable
ocally advanced tumour, who could be candidates for local therapy
surgery or CRT).
Several studies have also suggested that the intensity of FDG
umour uptake could be predictive of progression-free survival
PFS) and OS, as lesions with a higher SUV max  are associated with
horter survival [81–83].
.4. Detection of recurrenceThe value of PET/CT in the diagnosis of pancreatic carcinoma
ecurrence was reviewed in 2011. This review demonstrated an
mproved evaluation of cancer recurrence, especially in patientsr Disease 47 (2015) 443–454
with elevated tumour markers and normal or equivocal CT ﬁndings
[84].
4.5. Radiotherapy treatment planning
PET/CT has been suggested to be potentially useful for radiother-
apy treatment planning in small series of patients, by providing a
more accurate delineation of gross tumour volume compared to CT
alone [85,86], but these data need to be validated.
4.6. Current guidelines
The FFCD, NCCN, and ESMO consider that the role of PET/CT in
pancreatic cancer remains unclear [9,42,87]. However, the NCCN
suggests considering PET/CT after normal contrast-enhanced CT
scan in patients at high risk of developing distant metastases
(deﬁned as borderline resectable disease, markedly elevated CA19-
9, large primary tumours, and large regional lymph nodes). Thus,
all these data need to be conﬁrmed, including those concerning the
value of PET/CT in radiotherapy treatment planning.
5. Colorectal cancer
5.1. Diagnosis of malignancy
Physiological uptake is frequently observed in the gastrointesti-
nal tract, and may  complicate the detection of colorectal cancer
(CRC). Classically, diffuse uptake can be considered to be a normal
variant, but can also be secondary to inﬂammation or use of certain
drugs, such as metformin that signiﬁcantly increases FDG uptake
in the colon and, to a lesser extent, the small intestine [88]. By con-
trast, focal uptake frequently indicates the presence of a malignant
or premalignant colonic lesion.
About 75–88% of incidental colonic focal uptakes correspond to
malignant or premalignant lesions on endoscopy; 28–67% of these
lesions are premalignant (dysplastic adenomas), 20–46% are ade-
nocarcinomas, and 13–30% are benign lesions (Table 2) [89–93].
The sensitivity of FDG-PET has been shown to be correlated with
the size and grade of dysplasia [94,95]. In a prospective study on 45
patients with a total of 58 colonic neoplasms (premalignant and
malignant lesions), Friedland et al. reported a sensitivity of PET
for cancer of 62%. This rate was 100% for cancers that were 2 cm
in diameter or larger. PET also detected 23% of the premalignant
lesions, of which 38% were between 2 and 2.9 cm in diameter, and
70% were 3 cm or larger [94].
Therefore, the presence of incidental colonic focal FDG  uptake,
regardless of its intensity, justiﬁes endoscopy [90,92] because
the SUV level cannot differentiate benign from premalignant and
malignant lesions (Fig. 2).
5.2. Initial staging
There is no evidence supporting the routine use of FDG-PET/CT
in the initial staging of CRC [96].
A recent study demonstrated that the sensitivity of FDG-PET/CT
for N staging was  low, with a pooled sensitivity of 43% and a speci-
ﬁcity of 88% [97].
Although the use of PET/CT as a preoperative imaging modality
results in a change in tumour stage in 27–39% of patients (either by
up-staging or down-staging) [96–103], it only has a limited impact
on treatment decisions [104,105].
Therefore, its use should be reserved to patients in whom con-
ventional imaging is equivocal regarding the presence of distant
metastases.
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Table  2
Main studies comparing incidental focal colonic ﬂuorodeoxyglucose uptakes detected on positron emission tomography/computed tomography image with histological
ﬁndings.
References n Conﬁrmed by endoscopy Pre-malignant Malignant Benign
Kamel et al. [87] 69 60 (87%) 29 (48%) 13 (22%) 18 (30%)
Israel  et al. [88] 28 24 (86%) 9 (37%) 11 (46%) 4 (17%)
Even-Sapir et al. [89] 29 25 (86%) 7 (28%) 11 (44%) 7 (28%)
Gutman et al. [90] 20 15 (75%) 10 (67%) 3 (20%) 2 (13%)
Lee  et al. [91] 34 30 (88%) 19 (63%) 10 (33%) 1 (4%)
Fig. 2. Staging of a man  with a tonsil lymphoma. Positron emission tomography maximum intensity projection image showing ﬂuorodeoxyglucose uptake in the tonsil
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bymphoma (standardized uptake value max  7.3) (a), but also uptake in the right lu
iopsy  and two  colonic focal uptakes in the sigmoid (standardized uptake value m
olonoscopy with biopsies, to an adenoma with low-grade dysplasia and an adenoc
.3. Preoperative evaluation of resectable metastases
MRI  is considered superior to CT and PET/CT for the detec-
ion and characterization of small lesions and for liver evaluation,
specially since the development of sequences such as diffusion-
eighted imaging (DWI) [106]. MRI  is also a good imaging
echnique for the detection of inconspicuous peritoneal carcino-
atosis [107].
PET/CT can be useful in the preoperative assessment of
esectable liver metastasis from CRC before surgical resection [96].
ET and PET/CT have been shown to be efﬁcient not only for the
etection of liver metastases, with reported sensitivities of around
0%, generally superior to those of CT [108,109], but also for initial
taging [110–113] and for suspicion of recurrence [113,114].
Performing PET/CT in addition to conventional imaging leads to
 change of patient management in more than one third of the cases
115], and avoids unnecessary laparotomy in a signiﬁcant propor-
ion of patients (37%) [116]. However, the efﬁciency of FDG-PET
nd PET/CT is strongly affected by neoadjuvant chemotherapy in
atients with potentially resectable liver metastases [117]. In these
atients, MRI  appears to be the most appropriate imaging modality
efore surgical resection [118,119].andardized uptake value max 4.2) (b) corresponding to a lung adenocarcinoma on
) (c) and in the rectum (standardized uptake value max 6.5) (d) corresponding, on
ma, respectively.
FDG-PET and PET/CT can provide added diagnostic information
compared with conventional imaging in patients after radiofre-
quency ablation of liver metastases and can be used to guide repeat
ablations [120].
Finally, PET/CT has been demonstrated to be useful in patients
with potentially resectable lung metastases by detecting extrapul-
monary lesions in about 20% of the patients, which can lead to a
change in treatment decisions [121,122].
5.4. Assessment of therapeutic efﬁcacy/prognosis
Metabolic response to chemotherapy assessed by FDG-PET is
correlated with clinical response, tumour biology, and disease-free
survival in metastatic CRC patients [128,129]; however, FDG-PET is
not superior to CT scan [110,130–134].
In primary rectal cancer, FDG-PET response correlates with
pathology better than other morphologic imaging modalities
[128,135–138], and has recently been demonstrated to be useful
to identify patients achieving complete response to CRT, thus sug-
gesting that it could help for the selection of patients suitable for
a “watch and wait” strategy to avoid radical rectal resection [139].
4 d Liver Disease 47 (2015) 443–454
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his strategy needs to be validated in prospective randomized tri-
ls.
.5. Detection of recurrence
There is no indication to perform PET/CT in the routine follow-
p of CRC patients, even in those at high risk of recurrence
96,122]. However, FDG-PET/CT is well established as a reliable
maging method, and has shown accuracy and sensitivity higher
han those of CT and similar to those of MRI  for the early detec-
ion of recurrence sites accessible to curative surgical resection
n patients with elevated serum CEA (regardless of the CEA level)
110,113,123–127].
.6. Radiotherapy treatment planning in rectal cancer
CT and MRI  are the most commonly used methods for planning
f radiation therapy in patients with rectal cancer. The perfor-
ances of both these techniques in differentiating a malignant
esion from surrounding inﬂammatory changes or ﬁbrosis have
een evaluated. MRI  is currently considered to be the most accu-
ate staging method for rectal cancer [140–142], but its role in the
recise determination of the boost volume remains unclear [143].
It has been reported that the use of PET/CT for radiotherapy
lanning could minimize portal ﬁeld sizes without missing macro-
copic tumour tissue adjacent to the primary tumour, could be
seful for planning the boost volume for adjuvant radiation ther-
py after tumour resection (in this case PET/CT must be performed
n the radiotherapy position before surgery), and could increase
he inter-observer agreement concerning deﬁnition of the gross
umour volume [144–147].
.7. Current guidelines
According to the latest FFCD, NCCN, and ESMO guidelines,
ET/CT is not routinely indicated for initial staging, therapeutic
ssessment and follow-up in CRC [9,42,148–150]. However, it can
e performed in addition to MRI  in the case of resectable metastatic
isease (initial workup or recurrence) to exclude the presence of
ther metastatic sites [42,148–150]. The FFCD and NCCN also rec-
mmend considering PET/CT in the case of serial CEA elevation,
fter normal colonoscopy and CT scan for colon cancer, and as ﬁrst-
ine imaging in the case of rectal cancer [9,42].
Finally, colonoscopy is highly recommended in the case of inci-
ental focal colonic FDG uptake on PET/CT, as it frequently indicates
he presence of a malignant or premalignant colonic lesion.
. Anal canal cancer (squamous cell carcinoma)
.1. Initial staging
PET and PET/CT have a high sensitivity, ranging from 91% to
00%, for the detection of primary anal tumours [151–154]. Many
tudies have demonstrated the value of FDG-PET and PET/CT in the
taging of anal cancer in immunocompetent patients, with a high
ensitivity for the detection of inguinal and pelvic node involve-
ent or distant metastases that are not evident either clinically or
n CT scan [151–158] (Fig. 3). This has led to a change in the initial
taging of the disease in 47% of the cases: 20% by up-staging and
7% by down-staging [157]. These changes in staging are estimated
o have a subsequent impact on the planning of deﬁnitive radio-
herapy ﬁelds (12.6–35%) and, more generally, on the therapeutic
trategy [152–154,159,160].
SUVmax does not seem to be related to histology type or primary
umour size on physical examination, but could be affected by HIV
Fig. 3. Initial staging of a woman with squamous cell carcinoma of the anal canal.
Sagittal fused positron emission tomography/computed image showing uptake in
the  anal primary tumour (standardized uptake value max  20.7) (a) and in a presacral
mass  (standardized uptake value max  13.2) (b).
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tatus and seems to be higher when associated with lymph node
nvolvement at diagnosis [161].
.2. Assessment of therapeutic efﬁcacy/prognosis
A recent study performed on 39 patients demonstrated that the
otal MTV  (MTV-T), deﬁned as the sum of the volumes above a stan-
ardized uptake value of 50% of the SUVmax within the primary
umour and the involved nodes, may  be a clinically relevant prog-
ostic marker. In fact, a higher pre-treatment MTV-T is associated
ith poorer OS, PFS, and Event-Free Survival [162]. In this study,
UVmax was not prognostic for any outcome [162].
Other studies have underlined the impact of post-treatment (>8
eeks) PET to conﬁrm complete response to CRT. Their results
howed that, after completion of CRT, a partial metabolic response
assessed by SUVmax) to the primary anal tumour is associated
ith poorer PFS and OS compared to the survival values follow-
ng a complete metabolic response [163,164]. In two studies, a PET
esponse was a stronger predictor of survival than pre-treatment T
r N stage [161,164]. Moreover, PET/CT assessment 3 months after
RT has been reported to have a sensitivity of 100%, a speciﬁcity of
7.4%, a PPV of 66%, and a NPV of 100% for the detection of persistent
isease [158].
No data are available concerning the value of PET/CT for early
ssessment of metabolic response during CRT.
These results suggest that PET biomarkers may  be more valuable
rognostic factors than the known clinical factors. However, the
linical and therapeutic impact of these biomarkers remains to be
emonstrated [162], and PET/CT performances need to be com-
ared to those of other imaging modalities (CT, endoanal
ltrasound, and pelvic MRI) for the evaluation of therapeutic
esponse.
.3. Detection of recurrence
The reported sensitivity, speciﬁcity, and NPV of FDG-PET/CT for
he detection of recurrent loco-regional disease are 93%, 81%, and
4%, respectively, resulting in an impact on management in 20% of
ases [165]. Moreover, FDG-PET/CT may  be able to detect additional
ites of disease sparing the patient unnecessary salvage surgery
165].
These results need to be further investigated and compared to
ther imaging modalities.
.4. Current guidelines
A recent review underlined the growing use of FDG-PET/CT in
nal canal cancer [166]. The NCCN recommends considering PET/CT
or staging T3–T4 N0 or any N+ disease in patients with anal canal
ancer, as well as T2-T4 N0 or any N+ disease in patients with an
nal margin lesion [42]. The NCCN also recommends considering
ET/CT for radiotherapy treatment planning [42]. The FFCD recom-
ends PET/CT for initial workup, and suggests it for assessment of
herapeutic efﬁcacy [9]. Because most patients with anal canal can-
er are treated with radiotherapy or CRT, and due to the presence of
rowing evidence concerning its role in the determination of radio-
herapy ﬁelds, we consider that PET/CT should be performed for any
tage of anal canal cancer. Similarly to what said for oesophageal
ancer, ﬁnding a positive or ambiguous distant metastasis at PET
hould not lead to denial of those therapeutic options, such as radio-
herapy, that may  be useful to control local symptoms. Increasing
vidence is accumulating about the role of PET/CT for assessment of
herapeutic response to CRT after 8 weeks, but the best metabolic
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may  have a special role in the staging of loco-regional recurrence
by excluding distant disease before proceeding to salvage surgery.
7. Other digestive malignancies
7.1. Gastrointestinal stromal tumours (GIST)
CT scan is the investigation of choice for staging and follow-up
of GIST. However, PET/CT is now well established as the imaging
modality of choice because of its high sensitivity in assessing early
therapeutic response to imatinib or other targeted therapies in GIST
[167–174]. Thus, PET/CT may  be useful in doubtful cases and when
early prediction of response is of special concern (e.g. preopera-
tive cytoreductive treatments). Its role in the follow-up of patients
obtaining an initial response to this therapy has been emphasized
by various authors, as metabolic imaging will presumably be able
to detect secondary drug resistance that does not present in the
form of growing tumour or appearance of new metastases [167].
Finally, it has been suggested that PET/CT could be a useful tool to
predict the malignant potential of GIST [175–178].
The NCCN recommends considering PET/CT in the initial staging
of GIST and in therapeutic evaluation when CT scan is ambiguous,
while the FFCD suggests it as an option.
7.2. Hepatocellular carcinoma
Several studies have demonstrated a wide range of levels of
glucose-6-phosphatase activity and glucose transporters in HCC,
leading to variable FDG uptake values [179–182].
With an overall sensitivity of 50–65%, FDG-PET/CT is not recom-
mended for the detection of HCC [182–185], although the addition
of CT images can be useful, as 70% of HCCs are visible on unenhanced
CT as hypodense lesions, and 20% as hyperdense lesions [186,187].
Nevertheless, recent studies have shown that FDG-PET uptake
may  be useful for tumour characterization, assessment of thera-
peutic response, and prognosis, since a higher FDG uptake has been
reported to correlate with higher-grade cancers and poorer prog-
nosis [188–194]. However, these ﬁndings remain to be validated.
It has also been demonstrated that tumour metabolic activity
assessed by FDG-PET/CT is an independent predictor of response
to transarterial chemoembolization, with a poorer OS in the group
of patients with high pre-treatment SUVmax ratio than in the low
SUVmax ratio group [195,196]. The role of FDG-PET/CT compared to
other imaging modalities, such as CT and MRI, needs to be assessed.
Finally, several studies have shown that FDG-PET/CT can
improve the clinical management of HCC patients by selecting liver
transplantation candidates [190,197–199].
According to the FFCD, NCCN, and ESMO guidelines, PET/CT is
presently not recommended in the diagnosis, staging, and manage-
ment of HCC. However, its use may  be considered in the diagnosis
of recurrence in case of increasing alpha-fetoprotein levels.
7.3. Cholangiocarcinoma and gallbladder cancer
Despite FDG-PET/CT has no statistically signiﬁcant advantage
over contrast-enhanced CT or MRI  in the diagnosis of primary bil-
iary tumours [200,201], it is useful for the detection of regional and
distal metastases that can affect patient management by excluding
the subject from surgery [202–205].
FDG-PET has been reported to have a good sensitivity (75–100%)
and speciﬁcity (80–89%) for the detection of primary gallbladder
cancer [201,206–208].However, the evidence supporting the use of PET in gallblad-
der cancer remains limited, and larger studies are necessary to
determine the potential of these techniques to inﬂuence patient
outcomes.
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Table  3
Recommendations for the use ﬂuorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal malignancies.
Cancer Diagnosis Initial workup Assessment of
therapeutic
efﬁcacy
Radiotherapy
treatment
planning
Recurrence workup
Esophageal and EGJ
cancers
No Yes (if no evidence of
metastatic disease)
Emerging
evidence
Yes No
Gastric cancer No No (may be considered
if curative surgery is
planned)
No No No
Pancreatic cancer No No (may be considered
if curative surgery is
planned)
No – No
HCC  No No No – May  be considered in case
of rising AFP
Cholangiocarcinoma
and  gallblader
No Emerging evidence – No
Colorectal cancer No
(colonoscopy is
recommended
in case of
incidental focal
colonic uptake)
No (should be
considered before
resection of metastatic
disease)
No – No (may be considered in
case of rising CEA and
ambiguous or negative CT)
Anal  canal cancer No Yes Emerging
evidence
Emerging
evidence
No (may be considered if
salvage surgery is planned)
GIST  No No (may be considered
if early response to
therapy is of
importance in
preoperative setting)
No (except if CT
is ambiguous)
– No
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RGJ, esophagogastric junction; HCC, hepatocellular carcinoma; GIST, gastrointestin
oembryonic antigen.
Although there is emerging evidence for the role of PET in the
nitial staging of cholangiocarcinoma and gallbladder cancer, its use
n these malignancies cannot be currently recommended.
. Conclusion
Despite not having demonstrated a survival advantage in any
igestive cancer, FDG-PET/CT presents growing evidence of its
sefulness in the management of gastrointestinal malignancies
Table 3). FDG-PET/CT is now considered to be an essential tool for
he initial staging of oesophageal and anal cancers, in which it may
lay a role in the assessment of response to chemo-radiotherapy.
he use of this technique may  also change the therapeutic strategy
specially in potentially resectable metastatic colorectal cancer, but
lso, to a lesser extent, in localized gastric and pancreatic cancers
y detecting distant metastatic sites. Nevertheless, the accuracy of
his therapeutic strategy modiﬁcation requires further evaluations.
The increasing use of PET/CT in oncology and in various other
iseases is responsible for the detection of numerous incidental
ocal colonic uptakes, which correspond to premalignant or malig-
ant lesions in more than 70% of cases. Colonoscopy is therefore
ighly recommended in these cases.
Furthermore, elevated tumour marker levels associated with
ormal conventional imaging should prompt clinicians to consider
erforming PET/CT that can detect tumour recurrence with a higher
ensitivity and may  help selecting candidates for salvage surgery.
onﬂict of interest
one declared.
eferences
[1] Kato H, Miyazaki T, Nakajima M,  et al. The incremental effect of positron emis-
sion tomography on diagnostic accuracy in the initial staging of oesophageal
carcinoma. Cancer 2005;103:148–56.
[2] Van Vliet EP, Heijenbrok-Kal MH,  Hunink MG,  et al. Staging investiga-
tions for oesophageal cancer: a meta-analysis. British Journal of Cancer
2008;98:547–57.omal tumor; CT, computed tomography scan; AFP, alpha-fetoprotein; CEA, carci-
[3] Lerut T, Flamen P, Ectors N, et al. Histopathologic validation of lymph node
staging with FDG-PET scan in cancer of the oesophagus and gastroesophageal
junction: a prospective study based on primary surgery with extensive lym-
phadenectomy. Annals of Surgery 2000;232:743–52.
[4] Yoon YC, Lee KS, Shim YM,  et al. Metastasis to regional lymph nodes in patients
with oesophageal squamous cell carcinoma: CT versus FDG PET for presurgical
detection prospective study. Radiology 2003;227:764–70.
[5] van Westreenen HL, Westerterp M,  Bossuyt PM,  et al. Systematic review of the
staging performance of 18F-ﬂuorodeoxyglucose positron emission tomogra-
phy  in oesophageal cancer. Journal of Clinical Oncology 2004;22:3805–12.
[6] Chatterton BE, Ho-Shon I, Lenzo N, et al. Multi-center prospective assessment
of  accuracy and impact on management of positron emission tomography
(PET) in oesophageal and gastroesophageal junction cancers (EC). Australian
PET  Data Collection Project. ASCO Annual Meeting Proceedings Part I. Journal
of  Clinical Oncology 2007;25:4534.
[7] Barber TW,  Duong CP, Leong T, et al. 18F-FDG PET/CT has a high impact on
patient management and provides powerful prognostic stratiﬁcation in the
primary staging of oesophageal cancer: a prospective study with mature sur-
vival data. Journal of Nuclear Medicine 2012;53:864–71.
[8] Sihvo EI, Räsänen JV, Knuuti MJ, et al. Adenocarcinoma of the oesophagus
and the esophagogastric junction: positron emission tomography improves
staging and prediction of survival in distant but not in locoregional disease.
Journal of Gastrointestinal Surgery 2004;8:988–96.
[9] Thésausus national de cancérologie digestive. Available at:
http://www.tncd.org/ [accessed 02.02.15].
[10] Courrech Staal EF, Aleman BM,  Boot H, et al. Systematic review of the bene-
ﬁts and risks of neoadjuvant chemoradiation for oesophageal cancer. British
Journal of Surgery 2010;97:1482–96.
[11] Sjoquist KM,  Burmeister BH, Smithers BM,  et al. Survival after neoadjuvant
chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:
an updated meta-analysis. Lancet Oncology 2011;12:681–92.
[12] van Hagen P, Hulshof MC,  van Lanschot JJ, et al. Preoperative chemoradiother-
apy for oesophageal or junctional cancer. New England Journal of Medicine
2012;366:2074–84.
[13] Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery
compared with chemoradiation alone in squamous cancer of the oesophagus:
FFCD 9102. Journal of Clinical Oncology 2007;25:1160–8.
[14] Stahl M,  Stuschke M,  Lehmann N, et al. Chemoradiation with and without
surgery in patients with locally advanced squamous cell carcinoma of the
oesophagus. Journal of Clinical Oncology 2005;23:2310–7. Erratum in: J Clin
Oncol 2006;24:531.
[15] Weber WA,  Ott K, Becker K, et al. Prediction of response to preopera-
tive chemotherapy in adenocarcinomas of the esophagogastric junction by
metabolic imaging. Journal of Clinical Oncology 2001;19:3058–65.
[16] Wieder HA, Brucher BLDM, Zimmermann F, et al. Time course of tumour
metabolic activity during chemoradiotherapy of oesophageal squamous
cell carcinoma and response to treatment. Journal of Clinical Oncology
2004;22:900–8.
d LiveM.  Gauthé et al. / Digestive an
[17] Song SY, Kim JH, Ryu JS, et al. FDG-PET in the prediction of patho-
logic response after neoadjuvant chemoradiotherapy in locally advanced,
resectable oesophageal cancer. International Journal of Radiation Oncology,
Biology, Physics 2005;63:1053–9.
[18] Levine EA, Farmer MR,  Clark P, et al. Predictive value of 18-ﬂuoro-
deoxyglucose-positron emission tomography (18F-FDG-PET) in the identiﬁ-
cation of responders to chemoradiation therapy for the treatment of locally
advanced oesophageal cancer. Annals of Surgery 2006;243:472–8.
[19] Westerterp M,  Omloo JM,  Sloof GW,  et al. Monitoring of response to pre-
operative chemoradiation in combination with hyperthermia in oesophageal
cancer by FDG-PET. International Journal of Hyperthermia 2006;22:
149–60.
[20] Ott K, Weber WA,  Lordick F, et al. Metabolic imaging predicts response, sur-
vival, and recurrence in adenocarcinomas of the esophagogastric junction.
Journal of Clinical Oncology 2006;24:4692–8.
[21] Wieder HA, Ott K, Lordick F, et al. Prediction of tumour response by PDG-
PET: comparison of the accuracy of single and sequential studies in patients
with adenocarcinomas of the esophagogastric junction. European Journal of
Nuclear Medicine and Molecular Imaging 2007;34:1925–32.
[22] Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and
to  guide treatment of adenocarcinoma of the oesophagogastric junction: the
MUNICON phase II trial. Lancet Oncology 2007;8:797–805.
[23] Roedl JB, Colen RR, Holalkere NS, et al. Adenocarcinomas of the oesopha-
gus: response to chemoradiotherapy is associated with decrease of metabolic
tumour volume as measured on PET/CT. Comparison to histopathologic and
clinical response evaluation. Radiotherapy and Oncology 2008;89:278–86.
[24] Vallböhmer D, Hölscher AH, Dietlein, et al. [18F]-Fluorodeoxyglucose-positron
emission tomography for the assessment of histopathologic response and
prognosis after completion of neoadjuvant chemoradiation in oesophageal
cancer. Annals of Surgery 2009;250:888–94.
[25] van Heijl M,  Omloo JM,  van Berge Henegouwen MI,  et al. Fluorodeoxyglucose
positron emission tomography for evaluating early response during neoad-
juvant chemoradiotherapy in patients with potentially curable oesophageal
cancer. Annals of Surgery 2011;253:56–63.
[26] Piessen G, Petyt G, Duhamel A, et al. Ineffectiveness of 18F-ﬂuorodeoxyglucose
positron emission tomography in the evaluation of tumor response after
completion of neoadjuvant chemoradiation in esophageal cancer. Annals of
Surgery 2013;258:66–76.
[27] Kato H, Nakajima M,  Sohda M,  et al. The clinical application of
(18)F-ﬂuorodeoxyglucose positron emission tomography to predict sur-
vival in patients with operable oesophageal cancer. Cancer 2009;115:
3196–203.
[28] Pan L, Gu P, Huang G, et al. Prognostic signiﬁcance of SUV on PET/CT in
patients with oesophageal cancer: a systematic review and meta-analysis.
European Journal of Gastroenterology and Hepatology 2009;21:1008–
15.
[29] Palie O, Michel P, Ménard JF, et al. The predictive value of treatment
response using FDG PET performed on day 21 of chemoradiotherapy in
patients with oesophageal squamous cell carcinoma. A prospective, multi-
centre study (RTEP3). European Journal of Nuclear Medicine and Molecular
Imaging 2013;40:1345–55.
[30] Lemarignier C, Di Fiore F, Marre C, et al. Pretreatment metabolic tumour vol-
ume  is predictive of disease-free survival and overall survival in patients with
oesophageal squamous cell carcinoma. European Journal of Nuclear Medicine
and  Molecular Imaging 2014;41:2008–16.
[31] Vera P, Dubray B, Palie O, et al. Monitoring tumour response during chemo-
radiotherapy: a parametric method using FDG-PET/CT images in patients with
oesophageal cancer. EJNMMI  Research 2014;4:12.
[32] Zhu W,  Xing L, Yue J, et al. Prognostic signiﬁcance of SUV on PET/CT in
patients with localised oesophagogastric junction cancer receiving neoadju-
vant chemotherapy/chemoradiation: a systematic review and meta-analysis.
British Journal of Radiology 2012;85:694–701.
[33] zum Büschenfelde CM,  Herrmann K, Schuster T, et al. (18)F-FDG PET-guided
salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esoph-
agogastric junction: the MUNICON II trial. Journal of Nuclear Medicine
2011;52:1189–96.
[34] Cuenca X, Hennequin C, Hindié E, et al. Evaluation of early response to con-
comitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients
with locally advanced oesophageal carcinomas. European Journal of Nuclear
Medicine and Molecular Imaging 2013;40:477–85.
[35] Monjazeb AM,  Riedlinger G, Aklilu M,  et al. Outcomes of patients with
oesophageal cancer staged with [18F]ﬂuorodeoxyglucose positron emis-
sion  tomography (FDG-PET): can post chemoradiotherapy FDG-PET predict
the  utility of resection. Journal of Clinical Oncology 2010;28:4714–
21.
[36] Moureau-Zabotto L, Touboul E, Lerouge D, et al. Impact of CT and 18F-
deoxyglucose positron emission tomography image fusion for conformal
radiotherapy in oesophageal carcinoma. International Journal of Radiation
Oncology, Biology, Physics 2005;63:340–5.
[37] Muijs CT, Schreurs LM,  Busz DM,  et al. Consequences of additional use of
PET information for target volume delineation and radiotherapy dose dis-
tribution for oesophageal cancer. Radiotherapy and Oncology 2009;93:447–
53.
[38] Leong T, Everitt C, Yuen K, et al. A prospective study to evaluate the impact
of  FDG-PET on CT-based radiotherapy treatment planning for oesophageal
cancer. Radiotherapy and Oncology 2006;78:254–61.r Disease 47 (2015) 443–454 451
[39] Kato H, Miyazaki T, Nakajima M,  et al. Value of positron emission tomogra-
phy in the diagnosis of recurrent oesophageal carcinoma. British Journal of
Surgery 2004;91:1004–9.
[40] Guo H, Zhu H, Xi Y, et al. Diagnostic and prognostic value of 18F-FDG PET/CT
for patients with suspected recurrence from squamous cell carcinoma of the
oesophagus. Journal of Nuclear Medicine 2007;48:1251–8.
[41] Teyton P, Metges JP, Atmani A, et al. Use of positron emission tomography in
surgery follow-up of oesophageal cancer. Journal of Gastrointestinal Surgery
2009;13:451–8.
[42] NCCN guidelines for utilization of PET and PET/CT. Available at:
http://www.nccn.org/professionals/physician gls/f guidelines.asp [accessed
22.05.14].
[43] Stahl M,  Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clin-
ical Practice Guidelines for diagnosis, treatment and follow-up. Annals of
Oncology 2013;24(Suppl. 6):651–6.
[44] Alakus H, Batur M,  Schmidt M,  et al. Variable 18F-ﬂuorodeoxyglucose uptake
in gastric cancer is associated with different levels of GLUT-1 expression.
Nuclear Medicine Communications 2010;31:532–8.
[45] Stahl A, Ott K, Weber WA,  et al. FDG PET imaging of locally advanced
gastric carcinomas: correlation with endoscopic and histopathological
ﬁndings. European Journal of Nuclear Medicine and Molecular Imaging
2003;30:288–95.
[46] Yoshioka T, Yamaguchi K, Kubota K, et al. Evaluation of 18F-FDG PET in patients
with advanced, metastatic, or recurrent gastric cancer. Journal of Nuclear
Medicine 2003;44:690–9.
[47] Kim SK, Kang KW,  Lee JS, et al. Assessment of lymph node metastases using
18F-FDG PET in patients with advanced gastric cancer. European Journal of
Nuclear Medicine and Molecular Imaging 2006;33:148–55.
[48] Yun M,  Lim JS, Noh SH, et al. Lymph node staging of gastric cancer using
(18)F-FDG PET: a comparison study with CT. Journal of Nuclear Medicine
2005;46:1582–8.
[49] Oh HH, Lee SE, Choi IS, et al. The peak-standardized uptake value (P-SUV)
by  preoperative positron emission tomography-computed tomography (PET-
CT)  is a useful indicator of lymph node metastasis in gastric cancer. Journal
of  Surgical Oncology 2011;104:530–3.
[50] Hur H, Kim SH, Kim W,  et al. The efﬁcacy of preoperative PET/CT for prediction
of curability in surgery for locally advanced gastric carcinoma. World Journal
of  Surgical Oncology 2010;8:86.
[51] Yamada A, Oguchi K, Fukushima M,  et al. Evaluation of 2-deoxy-2-[18F]ﬂuoro-
d-glucose positron emission tomography in gastric carcinoma: relation to
histological subtypes, depth of tumour invasion, and glucose transporter-1
expression. Annals of Nuclear Medicine 2006;20:597–604.
[52] Mukai K, Ishida Y, Okajima K, et al. Usefulness of preoperative FDG-PET for
detection of gastric cancer. Gastric Cancer 2006;9:192–6.
[53] Chen J, Cheong JH, Yun MJ,  et al. Improvement in preoperative stag-
ing  of gastric adenocarcinoma with positron emission tomography. Cancer
2005;103:2383–90.
[54] Kwee RM,  Kwee TC. Imaging in assessing lymph node status in gastric cancer.
Gastric Cancer 2009;12:6–22.
[55] Ha TK, Choi YY, Song SY, et al. F18-ﬂuorodeoxyglucose-positron emission
tomography and computed tomography is not accurate in preoperative
staging of gastric cancer. Journal of the Korean Surgical Society 2011;81:
104–10.
[56] Jadvar H, Tatlidil R, Garcia AA, et al. Evaluation of recurrent gastric malig-
nancy with [F-18]-FDG positron emission tomography. Clinical Radiology
2003;58:215–21.
[57] Lim JS, Kim MJ, Yun MJ,  et al. Comparison of CT and 18F-FDG pet for detecting
peritoneal metastasis on the preoperative evaluation for gastric carcinoma.
Korean Journal of Radiology 2006;7:249–56.
[58] Smyth E, Schöder H, Strong VE, et al. A prospective evaluation of the util-
ity of 2-deoxy-2-[(18) F]ﬂuoro-d-glucose positron emission tomography and
computed tomography in staging locally advanced gastric cancer. Cancer
2012;118:5481–8.
[59] Wu LM,  Hu JN, Hua J, et al. 18F-ﬂuorodeoxyglucose positron emission
tomography to evaluate recurrent gastric cancer: a systematic review and
meta-analysis. Journal of Gastroenterology and Hepatology 2012;27:472–80.
[60] Waddell T, Verheij M,  Allum W,  et al. Gastric cancer: ESMO-ESSO-ESTRO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals
of  Oncology 2013;24(Suppl. 6):657–63.
[61] Zimny M,  Bares R, Fass J, et al. Fluorine-18 ﬂuorodeoxyglucose positron emis-
sion  tomography in the differential diagnosis of pancreatic carcinoma: a
report of 106 cases. European Journal of Nuclear Medicine 1997;24:678–82.
[62] Delbeke D, Martin WH.  PET and PET/CT for pancreatic malignancies. Surgical
Oncology Clinics of North America 2010;19:235–54.
[63] Takanami K, Hiraide T, Tsuda M,  et al. Additional value of FDG PET/CT to
contrast-enhanced CT in the differentiation between benign and malignant
intraductal papillary mucinous neoplasms of the pancreas with mural nod-
ules. Annals of Nuclear Medicine 2011;25:501–10.
[64] Schick V, Franzius C, Beyna T, et al. Diagnostic impact of 18F-FDG PET-CT evalu-
ating solid pancreatic lesions versus endosonography, endoscopic retrograde
cholangio-pancreatography with intraductal ultrasonography and abdomi-
nal  ultrasound. European Journal of Nuclear Medicine and Molecular Imaging
2008;35:1775–85.
[65] Tang S, Huang G, Liu J, et al. Usefulness of 18F-FDG PET, combined FDG-PET/CT
and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Euro-
pean Journal of Radiology 2011;78:142–50.
4 d Live52 M. Gauthé et al. / Digestive an
[66] Hu SL, Yang ZY, Zhou ZR, et al. Role of SUV(max) obtained by 18F-FDG PET/CT
in patients with a solitary pancreatic lesion: predicting malignant potential
and  proliferation. Nuclear Medicine Communications 2013;34:533–9.
[67] van Kouwen MC,  Jansen JB, van Goor H, et al. FDG-PET is able to detect pancre-
atic  carcinoma in chronic pancreatitis. European Journal of Nuclear Medicine
and Molecular Imaging 2005;32:399–404.
[68] Lee TY, Kim MH,  Park do H, et al. Utility of 18F-FDG PET/CT for differentiation
of  autoimmune pancreatitis with atypical pancreatic imaging ﬁndings from
pancreatic cancer. American Journal of Roentgenology 2009;193:343–8.
[69] Kamisawa T, Takum K, Anjiki H, et al. FDGPET/CT ﬁndings of autoimmune
pancreatitis. Hepato-Gastroenterology 2010;57:447–50.
[70] Tann M,  Sandrasegaran K, Jennings SG, et al. Positron emission tomography
and computed tomography of cystic pancreatic masses. Clinical Radiology
2007;62:745–51.
[71] Sperti C, Pasquali C, Chierichetti F, et al. Value of 18-ﬂuorodeoxyglucose
positron emission tomography in the management of patients with cystic
tumors of the pancreas. Annals of Surgery 2001;234:675–80.
[72] Sperti C, Bissoli S, Pasquali C, et al. 18-Fluorodeoxyglucose positron emis-
sion tomography enhances computed tomography diagnosis of malignant
intraductal papillary mucinous neoplasms of the pancreas. Annals of Surgery
2007;246:932–7.
[73] Kauhanen SP, Komar G, Seppanen MP,  et al. A prospective diagnostic accuracy
study of (18)F-ﬂuorodeoxyglucose positron emission tomography/computed
tomography, multidetector row computed tomography, and magnetic reso-
nance imaging in primary diagnosis and staging of pancreatic cancer. Annals
of  Surgery 2009;250:957–63.
[74] Heinrich S, Goerres GW,  Schäfer M,  et al. Positron emission tomog-
raphy/computed tomography inﬂuences on the management of
resectable pancreatic cancer and its cost-effectiveness. Annals of Surgery
2005;242:235–324.
[75] Buchs NC, Buhler L, Bucher P, et al. Value of contrast-enhanced 18F-
ﬂuorodeoxyglucose positron emission tomography/computed tomography
in  detection and presurgical assessment of pancreatic cancer: a prospective
study. Journal of Gastroenterology and Hepatology 2011;26:657–62.
[76] Pakzad F, Groves AM,  Ell PJ. The role of positron emission tomography
in  the management of pancreatic cancer. Seminars in Nuclear Medicine
2006;36:248–56.
[77] Casneuf V, Delrue L, Kelles A, et al. Is combined 18F-ﬂuorodeoxyglucose-
positron emission tomography/computed tomography superior to positron
emission tomography or computed tomography alone for diagnosis, stag-
ing  and restaging of pancreatic lesions? Acta Gastroenterologica Belgica
2007;70:331–8.
[78] Strobel K, Heinrich S, Bhure U, et al. Contrast enhanced 18F-FDG PET/CT: 1-
stop-shop imaging for assessing the resectability of pancreatic cancer. Journal
of Nuclear Medicine 2008;49:1408–13.
[79] Bang S, Chung HW,  Park SW,  et al. The clinical usefulness of 18-
ﬂuorodeoxyglucose positron emission tomography in the differential
diagnosis, staging and response evaluation after concurrent chemiora-
diotherapy for pancreatic cancer. Journal of Clinical Gastroenterology
2006;40:923–9.
[80] Kuwatani M, Kawakami H, Eto K, et al. Modalities for evaluating chemothera-
peutic efﬁcacy and survival time in patients with advanced pancreatic cancer:
comparison between FDG-PET, CT, and serum tumour markers. Internal
Medicine 2009;48:867–75.
[81] Zimny M,  Fass J, Bares R, et al. Fluorodeoxyglucose positron emission tomog-
raphy and the prognosis of pancreatic carcinoma. Scandinavian Journal of
Gastroenterology 2000;35:883–8.
[82] Sperti C, Pasquali C, Chierichetti F, et al. 18-Fluorodeoxyglucose positron
emission tomography in predicting survival of patients with pancreatic car-
cinoma. Journal of Gastrointestinal Surgery 2003;7:953–9.
[83] Schellenberg D, Quon A, Minn AY, et al. 18-Fluorodeoxyglucose PET is prog-
nostic of progression free and overall survival in locally advanced pancreas
cancer treated with stereotactic radiotherapy. International Journal of Radi-
ation Oncology, Biology, Physics 2010;77:1420–5.
[84] Cameron K, Golan S, Simpson W,  et al. Recurrent pancreatic carci-
noma and cholangiocarcinoma: 18F-ﬂuorodeoxyglucose positron emission
tomography/computed tomography (PET/CT). Abdominal Imaging 2011;36:
463–71.
[85] Ford EC, Herman J, Yorke E, et al. (18)FFDG PET/CT for image-guided and inten-
sity modulated radiotherapy. Journal of Nuclear Medicine 2009;50:1655–65.
[86] Parlak C, Topkan E, Onal C, et al. Prognostic value of gross tumour volume
delineated by FDG-PET-CT based radiotherapy treatment planning in patients
with locally advanced pancreatic cancer treated with chemoradiotherapy.
Radiation Oncology 2012;7:37.
[87] Seufferlein T, Bachet JB, Van Cutsem E, et al. Pancreatic adenocarcinoma:
ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-
up. Annals of Oncology 2012;23(Suppl. 7):733–40.
[88] Gontier E, Fourme E, Wartski M,  et al. High and typical 18F-FDG bowel uptake
in patients treated with metformin. European Journal of Nuclear Medicine
and  Molecular Imaging 2008;35:95–9.
[89] Kamel EM,  Thumshirn M,  Truninger K, et al. Signiﬁcance of incidental
18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation
with endoscopic and histopathologic results. Journal of Nuclear Medicine
2004;45:1804–10.
[90] Israel O, Yefremov N, Bar-Shalom R, et al. PET/CT detection of unex-
pected gastrointestinal foci of 18F-FDG uptake: incidence, localizationr Disease 47 (2015) 443–454
patterns, and clinical signiﬁcance. Journal of Nuclear Medicine 2005;46:
758–62.
[91] Even-Sapir E, Lerman H, Gutman M,  et al. The presentation of malignant
tumours and pre-malignant lesions incidentally found on PET-CT. European
Journal of Nuclear Medicine and Molecular Imaging 2006;33:541–52.
[92] Gutman F, Alberini J-L, Wartski M,  et al. Incidental colonic focal
lesions detected by FDG PET/CT. American Journal of Roentgenology
2005;185:495–500.
[93] Lee JC, Hartnett GF, Hughes BGM, et al. The segmental distribution and clinical
signiﬁcance of colorectal ﬂuorodeoxyglucose uptake incidentally detected on
PET-CT. Nuclear Medicine Communications 2009;30:333–7.
[94] Friedland S, Soetikno R, Carlisle M,  et al. 18-Fluorodeoxyglucose positron
emission tomography has limited sensitivity for colonic adenoma and early
stage colon cancer. Gastrointestinal Endoscopy 2005;61:395–400.
[95] VanKouwen MCA, Nagengast FM,  Jansen JB, et al. (18F)-ﬂuoro-2-deoxy-d-
glucose positron emission tomography detects clinical relevant adenomas
of  the colon: a prospective study. Journal of Clinical Oncology 2005;23:
3713–7.
[96] Chan K, Welch S, Walker-Dilks C, et al. Evidence-based guideline recommen-
dations on the use of positron emission tomography imaging in colorectal
cancer. Clinical Oncology 2012;24:232–49.
[97] Lu YY, Chen JH, Ding HJ, et al. A systematic review and meta-analysis of
pretherapeutic lymph node staging of colorectal cancer by 18 F-FDG PET or
PET/CT. Nuclear Medicine Communications 2012;33:1127–33.
[98] Kosugi C, Saito N, Murakami K, et al. Positron emission tomography for
preoperative staging in patients with locally advanced or metastatic col-
orectal adenocarcinoma in lymph node metastasis. Hepato-Gastroenterology
2008;55:398–402.
[99] Akiyoshi T, Oya M,  Fujimoto Y, et al. Comparison of preoperative whole-body
positron emission tomography with MDCT in patients with primary colorectal
cancer. Colorectal Disease 2009;11:464–9.
[100] Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature
for whole-body FDG PET detection of recurrent colorectal cancer. Journal of
Nuclear Medicine 2000;41:1177–89.
[101] Heriot A, Hicks R, Drummond E, et al. Does positron emission tomography
change management in primary rectal cancer. A prospective assessment.
Diseases of the Colon and Rectum 2004;47:451–8.
[102] Gearhart S, Frassica D, Rosen R, et al. Improved staging with pretreatment
positron emission tomography/computed tomography in low rectal cancer.
Annals of Surgical Oncology 2006;13:397–404.
[103] Wiratkapun S, Kraemer M,  Seow-Choen F, et al. High preoperative serum car-
cinoembryonic antigen predicts metastatic recurrence in potentially curative
colonic cancer: results of a ﬁve-year study. Diseases of the Colon and Rectum
2001;44:231–5.
[104] Cipe G, Ergul N, Hasbahceci M,  et al. Routine use of positron-emission
tomography/computed tomography for staging of primary colorectal
cancer: does it affect clinical management? World Journal of Surgical Oncol-
ogy  2013;11:49.
[105] Eglinton T, Luck A, Bartholomeusz D, et al. Positron emission tomogra-
phy/computed tomography (PET/CT) in the initial staging of primary rectal
cancer. Colorectal Disease 2010;12:667–73.
[106] Sahani DV, Bajwa MA, Andrabi Y, et al. Current status of imaging and emerging
techniques to evaluate liver metastases from colorectal carcinoma. Annals of
Surgery 2014;259:861–72.
[107] González-Moreno S, González-Bayón L, Ortega-Pérez G, et al. Imaging of peri-
toneal carcinomatosis. Cancer Journal 2009;15:184–9.
[108] Floriani II, Torri V, Rulli E, et al. Performance of imaging modalities in diagnosis
of liver metastases from colorectal cancer: a systematic review and meta-
analysis. Journal of Magnetic Resonance Imaging 2010;31:19–31.
[109] Wiering B, Krabbe PF, Jager GJ, et al. The impact of ﬂuor-18-deoxyglucose-
positron emission tomography in the management of colorectal liver
metastases. Cancer 2005;104:2658–70.
[110] Facey K, Bradbury I, Laking G, et al. Overview of the clinical effectiveness of
positron emission tomography imaging in selected cancers. Health Technol-
ogy Assessment 2007;11:iii–v, xi-267.
[111] Cohade C, Osman M,  Leal J, et al. Direct comparison of (18) F-FDG PET and
PET/CT in patients with colorectal carcinoma. Journal of Nuclear Medicine
2003;44:1797–803.
[112] Liu Y, Huang M,  An Q, et al. The impact of PET/CT on therapeutic strat-
egy of patients with colorectal cancer metastasis. Hepato-Gastroenterology
2009;56:968–70.
[113] Metser U, You J, McSweeney S, et al. Assessment of tumour recurrence in
patients with colorectal cancer and elevated carcinoembryonic antigen level:
FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
American Journal of Roentgenology 2010;194:766–71.
[114] Kitajima K, Murakami K, Yamasaki E, et al. Performance of integrated FDG
PET/contrast-enhanced CT in the diagnosis of recurrent colorectal can-
cer: comparison with integrated FDG PET/non-contrast-enhanced CT and
enhanced CT. European Journal of Nuclear Medicine and Molecular Imaging
2009;36:1388–96.
[115] Deandreis D, Leboulleux S, Dromain C, et al. Role of FDG PET/CT and chest CT in
the follow-up of lung lesions treated with radiofrequency ablation. Radiology
2011;258:270–6.
[116] Ruers TJM, Wiering B, van der Sijp JRM, et al. Improved selection of patients for
hepatic surgery of colorectal liver metastases with 18F-FDG PET: a randomized
study. Journal of Nuclear Medicine 2009;50:1036–41.
d Live
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[M.  Gauthé et al. / Digestive an
117] Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver
resection for patients with unresectable liver metastases from colorectal car-
cinoma. Journal of Clinical Oncology 2005;23:2038–48.
118] van Kessel CS, Buckens CF, van den Bosch MA,  et al. Preoperative imaging of
colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis.
Annals of Surgical Oncology 2012;19:2805–13.
119] Adie S, Yip C, Chu F, et al. Resection of liver metastases from colorectal cancer:
does preoperative chemotherapy affect the accuracy of PET in preoperative
planning. ANZ Journal of Surgery 2009;79:358–61.
120] Barker DW,  Zagoria RJ, Morton KA, et al. Evaluation of liver metastases after
radiofrequency ablation: utility of 18F-FDG PET and PET/CT. American Journal
of  Roentgenology 2005;184:1096–102.
121] Kodama H, Yamakado K, Takaki H, et al. Impact of 18F-FDG-PET/CT on treat-
ment strategy in colorectal cancer lung metastasis before lung radiofrequency
ablation. Nuclear Medicine Communications 2013;34:689–93.
122] Patel K, Hadar N, Lee J, et al. The lack of evidence for PET or PET/CT surveillance
of patients with treated lymphoma, colorectal cancer, and head and neck
cancer: a systematic review. Journal of Nuclear Medicine 2013;54:1518–27.
123] Ozkan E, Soydal C, Araz M,  et al. The role of 18F-FDG PET/CT in detecting
colorectal cancer recurrence in patients with elevated CEA levels. Nuclear
Medicine Communications 2012;33:395–402.
124] Chen LB, Tong JL, Song HZ, et al. (18)F-DG PET/CT in detection of recur-
rence and metastasis of colorectal cancer. World Journal of Gastroenterology
2007;13:5025–9.
125] Kyoto Y, Momose M,  Kondo C, et al. Ability of 18F-FDG PET/CT to diagnose
recurrent colorectal cancer in patients with elevated CEA concentrations.
Annals of Nuclear Medicine 2010;24:395–401.
126] Lu YY, Chen JH, Chien CR, et al. Use of FDG-PET or PET/CT to detect recur-
rent colorectal cancer in patients with elevated CEA: a systematic review and
meta-analysis. International Journal of Colorectal Disease 2013;28:1039–47.
127] Sobhani I, Tiret E, Lebtahi R, et al. Early detection of recurrence by 18FDG-PET
in  the follow-up of patients with colorectal cancer. British Journal of Cancer
2008;98:875–80.
128] de Geus-Oei LF, Vriens D, van Laarhoven HW,  et al. Monitoring and predict-
ing response to therapy with 18F-FDG PET in colorectal cancer: a systematic
review. Journal of Nuclear Medicine 2009;50(Suppl. 1):43S–54S.
129] Hendlisz A, Golﬁnopoulos V, Garcia C, et al. Serial FDG-PET/CT for early out-
come prediction in patients with metastatic colorectal cancer undergoing
chemotherapy. Annals of Oncology 2012:1687–93.
130] Lee JE, Kim SW,  Kim JS, et al. Prognostic value of 18-ﬂuorodeoxyglucose
positron emission tomography-computed tomography in resectable colorec-
tal cancer. World Journal of Gastroenterology 2012;18:5072–7.
131] Bystrom P, Berglund A, Garske U, et al. Early prediction of response to ﬁrst-
line chemotherapy by sequential [18F]-2-ﬂuoro-2-deoxy-d-glucose positron
emission tomography in patients with advanced colorectal cancer. Annals of
Oncology 2009;20:1057–61.
132] Capirci C, Rubello D, Chierichetti F, et al. Long-term prognostic value of 18F-
FDG PET in patients with locally advanced rectal cancer previously treated
with neoadjuvant radiochemotherapy. American Journal of Roentgenology
2006;187:202–8.
133] Kalff V, Duong C, Drummond EG, et al. Findings on 18F-FDG PET scans after
neoadjuvant chemoradiation provides prognostic stratiﬁcation in patients
with locally advanced rectal carcinoma subsequently treated by radical
surgery. Journal of Nuclear Medicine 2006;47:14–22.
134] Cascini GL, Avallone A, Delrio P, et al. 18F-FDG PET is an early predictor of
pathologic tumour response to preoperative radiochemotherapy in locally
advanced rectal cancer. Journal of Nuclear Medicine 2006;47:1241–8.
135] Zhang C, Tong J, Sun X, et al. 18F-FDG-PET evaluation of treatment response
to neo-adjuvant therapy in patients with locally advanced rectal cancer: a
meta-analysis. International Journal of Cancer 2012;131:2604–11.
136] Murcia Duréndez MJ, Frutos Esteban L, Luján J, et al. The value of 18F-FDG
PET/CT for assessing the response to neoadjuvant therapy in locally advanced
rectal cancer. European Journal of Nuclear Medicine and Molecular Imaging
2013;40:91–7.
137] Perez RO, Habr-Gama A, Gama-Rodrigues J, et al. Accuracy of positron
emission tomography/computed tomography and clinical assessment in the
detection of complete rectal tumour regression after neoadjuvant chemora-
diation: long-term results of a prospective trial (National Clinical Trial
00254683). Cancer 2012;118:3501–11.
138] Perez RO, Habr-Gama A, São Julião GP, et al. Clinical relevance of
positron emission tomography/computed tomography-positive inguinal
nodes in rectal cancer after neoadjuvant chemoradiation. Colorectal Disease
2013;15:674–82.
139] Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and wait approach
following extended neoadjuvant chemoradiation for distal rectal cancer: are
we  getting closer to anal cancer management? Diseases of the Colon and
Rectum 2013;56:1109–17.
140] Beets-Tan RG, Beets GL, Vliegen RF, et al. Accuracy of magnetic resonance
imaging in prediction of tumour-free resection margin in rectal cancer
surgery. Lancet 2001;357:497–504.
141] Beets-Tan RG, Beets GL. Rectal cancer: how accurate can imaging predict
the T stage and the circumferential resection margin. International Journal
of  Colorectal Disease 2003;18:385–91.
142] Mercury SG. Diagnostic accuracy of preoperative magnetic resonance imaging
in predicting curative resection of rectal cancer: prospective observational
study. British Medical Journal 2006;333:779.r Disease 47 (2015) 443–454 453
[143] Lambrecht M,  Haustermans K. Clinical evidence on PET–CT for radiation
therapy planning in gastro-intestinal tumors. Radiotherapy and Oncology
2010;96:339–46.
[144] Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with
an integrated positron emission International Journal of Surgical Oncology
and computer tomography (PET/CT): a feasibility study. International Journal
of  Radiation Oncology, Biology, Physics 2003;57:853–63.
[145] Buijsen J, van den Bogaard J, van der Weide H, et al. FDG-PET-CT reduces
the  interobserver variability in rectal tumour delineation. Radiotherapy and
Oncology 2012;102:371–6.
[146] Buijsen J, Van den Bogaard J, Janssen MH,  et al. FDG–PET provides the best cor-
relation with the tumour specimen compared to MRI  and CT in rectal cancer.
Radiotherapy and Oncology 2011;98:270–6.
[147] Peeters KC, Van de Velde CJ, Leer JW,  et al. Late side effects of short-course
preoperative radiotherapy combined with total mesorectal excision for rectal
cancer: increased bowel dysfunction in irradiated patients – a Dutch colorec-
tal cancer group study. Journal of Clinical Oncology 2005;23:6199–206.
[148] Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO clin-
ical practice guidelines for diagnosis, treatment and follow-up. Annals of
Oncology 2013;24(Suppl. 6).
[149] Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO
clinical practice guidelines for treatment. Annals of Oncology 2010;21(Suppl.
5):593–7.
[150] Glimelius B, Tiret E, Cervantes A, et al. Rectal cancer: ESMO clinical prac-
tice  guidelines for diagnosis, treatment and follow-up. Annals of Oncology
2013;24(Suppl. 6):681–8.
[151] Sveistrup J, Loft A, Berthelsen AK, et al. Positron emission tomogra-
phy/computed tomography in the staging and treatment of anal cancer. Inter-
national Journal of Radiation Oncology, Biology, Physics 2012;83:134–41.
[152] Cotter SE, Grigsby PW,  Siegel BA, et al. FDG-PET/CT in the evaluation of
anal carcinoma. International Journal of Radiation Oncology, Biology, Physics
2006;65:720–5.
[153] Nguyen BT, Joon DL, Khoo V, et al. Assessing the impact of FDG-PET
in  the management of anal cancer. Radiotherapy and Oncology 2008;87:
376–82.
[154] de Winton E, Heriot AG, Ng M,  et al. The impact of 18-ﬂuorodeoxyglucose
positron emission tomography on the staging, management and outcome of
anal  cancer. British Journal of Cancer 2009;100:693–700.
[155] Trautmann TG, Zuger JH. Positron emission tomography for pretreatment
staging and post treatment evaluation in cancer of the anal canal. Molecular
Imaging and Biology 2005;7:309–13.
[156] Iagaru A, Kundu R, Jadvar H, et al. Evaluation by 18F-FDG-PET of patients
with anal squamous cell carcinoma. Hellenic Journal of Nuclear Medicine
2009;12:26–9.
[157] Wells IT, Fox BM.  PET/CT in anal cancer – is it worth doing. Clinical Radiology
2012;67:535–40.
[158] Mistrangelo M,  Pelosi E, Bellò M,  et al. Role of positron emission tomography-
computed tomography in the management of anal cancer. International
Journal of Radiation Oncology, Biology, Physics 2012;84:66–72.
[159] Anderson C, Koshy M, Staley C, et al. PET-CT fusion in radiation management of
patients with anorectal tumors. International Journal of Radiation Oncology,
Biology, Physics 2007;69:155–62.
[160] Renaud S, Guillermand S, Eberlé-Pouzeratte MC,  et al. Contribution of
18F-ﬂuorodeoxyglucose positron emission tomography (FDG-PET) in the
management of anal carcinoma. Médecine Nucléaire 2009;33:415–24.
[161] Kidd EA, Dehdashti F, Siegel BA, et al. Anal cancer maximum F-18 ﬂuo-
rodeoxyglucose uptake on positron emission tomography is correlated with
prognosis. Radiotherapy and Oncology 2010;95:288–91.
[162] Bazan JG, Koong AC, Kapp DS, et al. Metabolic tumour volume predicts disease
progression and survival in patients with squamous cell carcinoma of the anal
canal. Journal of Nuclear Medicine 2013;54:27–32.
[163] Schwarz JK, Siegel BA, Dehdashti F, et al. Tumor response and survival pre-
dicted by post-therapy FDG-PET/CT in anal cancer. International Journal of
Radiation Oncology, Biology, Physics 2008;71:180–6.
[164] Day FL, Link E, Ngan S, et al. FDG-PET metabolic response predicts outcomes
in  anal cancer managed with chemoradiotherapy. British Journal of Cancer
2011;105:498–504.
[165] Vercellino L, Montravers F, de Parades V, et al. Impact of FDG PET/CT in the
staging and the follow-up of anal carcinoma. International Journal of Colorec-
tal  Disease 2011;26:201–10.
[166] Saboo SS, Zukotynski K, Shinagare AB, et al. Anal carcinoma: FDG
PET/CT in staging, response evaluation, and follow-up. Abdominal Imaging
2013;38:728–35.
[167] Basu S, Mohandas KM,  Peshwe H, et al. FDG-PET and PET/CT in the clinical
management of gastrointestinal stromal tumour. Nuclear Medicine Commu-
nications 2008;29:1026–39.
[168] Treglia G, Mirk P, Stefanelli A, et al. 18F-ﬂuorodeoxyglucose positron emis-
sion  tomography in evaluating treatment response to imatinib or other drugs
in gastrointestinal stromal tumors: a systematic review. Clinical Imaging
2012;36:167–75.
[169] Demetri GD, von Mehren M,  Blanke CD, et al. Efﬁcacy and safety of imatinib
mesylate in advanced gastrointestinal stromal tumors. New England Journal
of  Medicine 2002;347:472–80.
[170] Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early pre-
diction of response to therapy of recurrent gastrointestinal stromal tumors.
Journal of Nuclear Medicine 2004;45:17–21.
4 d Live54 M. Gauthé et al. / Digestive an
[171] Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-
modality PET/CT imaging for monitoring of imatinib (ST1571) therapy in
patients with gastrointestinal stromal tumors. Journal of Nuclear Medicine
2004;45:357–65.
[172] Basu S, Nair N, Peshwe H, et al. Potential role of FDG-PET to assess response
to  imatinib mesylate therapy and detecting viable disease in gastrointestinal
stromal tumors (GIST). Journal of Nuclear Medicine 2004;45(Suppl.):89.
[173] Goerres GW,  Stupp R, Barghouth G, et al. The value of PET, CT and in-line
PET/CT in patients with gastrointestinal stromal tumours: long-term outcome
of  treatment with imatinib mesylate. European Journal of Nuclear Medicine
and Molecular Imaging 2005;32:153–62.
[174] Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography
and positron emission tomography in patients with metastatic gastrointesti-
nal stromal tumour treated at a single institution with imatinib mesylate:
proposal of new computed tomography response criteria. Journal of Clinical
Oncology 2007;25:1753–9.
[175] Yoshikawa K, Shimada M,  Kurita N, et al. The efﬁcacy of PET–CT for predicting
the malignant potential of gastrointestinal stromal tumors. Surgery Today
2013;43:1162–7.
[176] Kamiyama Y, Aihara R, Nakabayashi T, et al. 18F-ﬂuorodeoxyglucose positron
emission tomography: useful technique for predicting malignant potential of
gastrointestinal stromal tumors. World Journal of Surgery 2005;29:1429–35.
[177] Yamada M,  Niwa Y, Matsuura T, et al. Gastric GIST malignancy evaluated by
18F DG-PET as compared with EUS-FNA and endoscopic biopsy. Scandinavian
Journal of Gastroenterology 2007;42:633–41.
[178] Park JW,  Cho CH, Jeong DS, et al. Role of F-ﬂuoro-2-deoxyglucose positron
emission tomography in gastric GIST: predicting malignant potential pre-
operatively. Journal of Gastric Cancer 2011;11:173–9.
[179] Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose
metabolism in hepatocellular carcinoma with FDG-PET. Journal of Nuclear
Medicine 1995;36:1811–7.
[180] Salem N, MacLennan GT, Kuang Y, et al. Quantitative evaluation of 2-
deoxy-2[F-18]ﬂuoro-d-glucose-positron emission tomography imaging on
the woodchuck model of hepatocellular carcinoma with histological corre-
lation. Molecular Imaging and Biology 2007;9:135–43.
[181] Lee JD, Yang WI,  Park YN, et al. Different glucose uptake and glycolytic mech-
anisms between hepatocellular carcinoma and intrahepatic mass forming
cholangiocarcinoma with increased (18) F-FDG uptake. Journal of Nuclear
Medicine 2005;46:1753–9.
[182] Roh MS,  Jeong JS, Kim YH, et al. Diagnostic utility of GLUT1 in the differential
diagnosis of liver carcinomas. Hepato-Gastroenterology 2004;51:1315–8.
[183] Khan MA,  Combs CS, Brunt EM,  et al. Positron emission tomography scan-
ning in the evaluation of hepatocellular carcinoma. Journal of Hepatology
2000;32:792–7.
[184] Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma
and other liver masses. Journal of Nuclear Medicine 2003;44:213–21.
[185] Rose AT, Rose DM,  Pinson CW,  et al. Hepatocellular carcinoma outcomes based
on  indicated treatment strategy. American Surgeon 1998;64:1128–34.
[186] Czernin J, Schelbert HR. PET/CT in cancer patient management: introduction.
Journal of Nuclear Medicine 2007;48(Suppl. 1):2S–3S.
[187] Iannaccone R, Piacentini F, Murakami T, et al. Hepatocellular carcinoma
in  patients with nonalcoholic fatty liver disease: helical CT and MR
imaging ﬁndings with clinical-pathologic comparison. Radiology 2007;243:
422–30.
[188] Higashi T, Hatano E, Ikai I, et al. FDG PET as a prognostic predictor in the early
post-therapeutic evaluation for unresectable hepatocellular carcinoma. Euro-
pean Journal of Nuclear Medicine and Molecular Imaging 2010;37:468–82.
[189] Lee JH, Park JY, Kim do Y, et al. Prognostic value of 18F-FDG PET for hep-
atocellular carcinoma patients treated with sorafenib. Liver International
2011;31:1144–9.
[190] Kornberg A, Kupper B, Tannapfel A, et al. Patients with non-
[18F]ﬂudeoxyglucose-avid advanced hepatocellular carcinoma on clinical
staging may achieve long-term recurrence-free survival after liver
transplantation. Liver Transplantation 2012;18:53–61.r Disease 47 (2015) 443–454
[191] Ahn SG, Kim SH, Jeon TJ, et al. The role of preoperative [18F]ﬂuorodeoxyglucose
positron emission tomography in predicting early recurrence after curative
resection of hepatocellular carcinomas. Journal of Gastrointestinal Surgery
2011;15:2044–52.
[192] Kim BK, Kang WJ,  Kim JK, et al. (18)F-ﬂuorodeoxyglucose uptake on positron
emission tomography as a prognostic predictor in locally advanced hepato-
cellular carcinoma. Cancer 2011;117:4779–87.
[193] Hatano E, Ikai I, Higashi T, et al. Preoperative positron emission tomography
with ﬂuorine-18-ﬂuorodeoxyglucose is predictive of prognosis in patients
with hepatocellular carcinoma after resection. World Journal of Surgery
2006;30:1736–41.
[194] Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of
extrahepatic metastases from hepatocellular carcinoma. Journal of Gastroen-
terology 2004;39:961–8.
[195] Song MJ,  Bae SH, Lee SW,  et al. 18F-ﬂuorodeoxyglucose PET/CT predicts
tumour progression after transarterial chemoembolization in hepatocellu-
lar carcinoma. European Journal of Nuclear Medicine and Molecular Imaging
2013;40:865–73.
[196] Song MJ,  Bae SH, Yoo Ie R, et al. Predictive value of 18F-ﬂuorodeoxyglucose
PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma.
World Journal of Gastroenterology 2012;18:3215–22.
[197] Kim YK, Lee KW,  Cho SY, et al. Usefulness 18F-FDG positron emission
tomography/computed tomography for detecting recurrence of hepa-
tocellular carcinoma in post-transplant patients. Liver Transplantation
2010;16:767–72.
[198] Yang SH, Suh KS, Lee HW,  et al. The role of (18)F-FDG-PET imaging for the
selection of liver transplantation candidates among hepatocellular carcinoma
patients. Liver Transplantation 2006;12:1655–60.
[199] Kornberg A, Kupper B, Thrum K, et al. Increased 18F-FDG uptake of hepato-
cellular carcinoma on positron emission tomography independently predicts
tumour recurrence in liver transplant patients. Transplantation Proceedings
2009;41:2561–3.
[200] Kim JY, Kim MH,  Lee TY, et al. Clinical role of 18F-FDG PET-CT in sus-
pected and potentially operable cholangiocarcinoma: a prospective study
compared with conventional imaging. American Journal of Gastroenterology
2008;103:1145–51.
[201] Petrowsky H, Wildbrett P, Husarik DB, et al. Impact of integrated positron
emission tomography and computed tomography on staging and manage-
ment of gallbladder cancer and cholangiocarcinoma. Journal of Hepatology
2006;45:43–50.
[202] Jadvar H, Henderson RW,  Conti PS. [F-18]ﬂuorodeoxyglucose positron
emission tomography and positron emission tomography: computed tomog-
raphy in recurrent and metastatic cholangiocarcinoma. Journal of Computer
Assisted Tomography 2007;31:223–8.
[203] Seo S, Hatano E, Higashi T, et al. Fluorine-18 ﬂuorodeoxyglucose positron
emission tomography predicts lymph node metastasis, P-glycoprotein
expression, and recurrence after resection in mass-forming intrahepatic
cholangiocarcinoma. Surgery 2008;143:769–77.
[204] Moon CM,  Bang S, Chung JB, et al. Usefulness of 18F-ﬂuorodeoxyglucose
positron emission tomography in differential diagnosis and staging of cholan-
giocarcinomas. Journal of Gastroenterology and Hepatology 2008;23:759–65.
[205] Corvera CU, Blumgart LH, Akhurst T, et al. 18F-ﬂuorodeoxyglucose positron
emission tomography inﬂuences management decisions in patients with
biliary cancer. Journal of the American College of Surgeons 2008;206:
57–65.
[206] Anderson CD, Rice MH,  Pinson CW,  et al. Fluorodeoxyglucose PET imaging in
the  evaluation of gallbladder carcinoma and cholangiocarcinoma. Journal of
Gastrointestinal Surgery 2004;8:90–7.
[207] Rodríguez-Fernández A, Gómez-Río M,  Llamas-Elvira JM,  et al. Positron-
emission tomography with ﬂuorine-18-ﬂuoro-2-deoxy-d-glucose for gall-
bladder cancer diagnosis. American Journal of Surgery 2004;188:171–5.
[208] Koh T, Taniguchi H, Yamaguchi A, et al. Differential diagnosis of gallbladder
cancer using positron emission tomography with ﬂuorine-18-labeled ﬂuo-
rodeoxyglucose (FDG-PET). Journal of Surgical Oncology 2003;84:74–81.
